Roche

Views & Analysis

R&D Roundup: Pharma gets in on the biotech boom

Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g

News

Roche insists Spark deal is still on, despite lacklustre tak...

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension to the tender process.

News

MS drug market heats up as FDA backs Novartis' new pill

The FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a potential blow to a much-delayed rival from Celgene.

News

Question marks over AbbVie/Roche's venetoclax after safety s...

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it tha

News

Roche's Tecentriq gains new US lung cancer indication

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination wi

News

EU expands use of Roche's new haemophilia A drug

The European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the use of the drug that is expected to drive sales as blockbus

R&D Roundup: Pharma gets in on the biotech boom

Roche insists Spark deal is still on, despite lacklustre tak...

MS drug market heats up as FDA backs Novartis' new pill

Question marks over AbbVie/Roche's venetoclax after safety s...

Roche's Tecentriq gains new US lung cancer indication

EU expands use of Roche's new haemophilia A drug

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Roche

Editor's Picks